REGULATORY

• Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
  May 27, 2025

• MSD’s Welireg, BMS’ Inrebic, J&J’s Talvey Up for Japan Panel Review on June 6
  May 26, 2025

• Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
  May 23, 2025

• Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
  May 22, 2025

• MHLW Orders Label Revisions for Diuretics, Zolgensma
  May 22, 2025

• LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
  May 22, 2025

• MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
  May 22, 2025

• OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
  May 22, 2025

• LDP Commission Mulls Proposal for Price Revisions That Enable Wage Hikes on Par with Other Industries
  May 21, 2025

• LDP’s Pharmaceutical Security League Reboots under New Chair
  May 21, 2025

• MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
  May 21, 2025

• LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
  May 20, 2025

• New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
  May 20, 2025

• Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
  May 20, 2025

• Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
  May 16, 2025

• Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
  May 16, 2025

• Biktarvy Gets Label Update to Add Eligible Patients
  May 16, 2025

• Regional Formulary Push Pops Up from Ishin at 3-Party Talks
  May 16, 2025

• Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More
  May 15, 2025

• Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
  May 15, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• …
• Next ›
• 最終 »